Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil D Christensen

Showing results (101-110 of 122) with videos related to

Pageof 13
Sort By:
The Journal of General Virology|September 26, 2017
Mouse papillomavirus infections spread to cutaneous sites with progression to malignancyNancy M Cladel, Lynn R Budgeon, Timothy K Cooper, et al.
Journal of Virology|June 15, 2022
RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human CancerPola Olczak, Ken Matsui, Margaret Wong, et al.
Journal of Virology|November 14, 2014
A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragmentHyunwook Lee, Sarah A Brendle, Stephanie M Bywaters, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 22, 2020
An Integrated Approach for Preventing Oral Cavity and Oropharyngeal Cancers: Two Etiologies with Distinct and Shared Mechanisms of CarcinogenesisKaram El-Bayoumy, Neil D Christensen, Jiafen Hu, et al.
Vaccine|September 19, 2015
Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopesSubhashini Jagu, Balusubramanyam Karanam, Joshua W Wang, et al.
Pathogens (Basel, Switzerland)|December 22, 2023
Immune Responses in Oral Papillomavirus Clearance in the MmuPV1 Mouse ModelSarah A Brendle, Jingwei J Li, Vonn Walter, et al.
Antimicrobial Agents and Chemotherapy|April 29, 2009
GS-9191 is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesionsGrushenka H I Wolfgang, Riri Shibata, Jianying Wang, et al.
Vaccine|May 27, 2006
Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopesKenneth E Palmer, Ann Benko, Sarah A Doucette, et al.
Virology|May 12, 2005
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2Diana V Pastrana, Ratish Gambhira, Christopher B Buck, et al.
Viruses|September 28, 2021
Mouse Papillomavirus L1 and L2 Are Dispensable for Viral Infection and Persistence at Both Cutaneous and Mucosal TissuesSarah Brendle, Jingwei J Li, Nancy M Cladel, et al.
Pageof 13

Showing results (101-110 of 122) with videos related to

Sort By:
Pageof 13
The Journal of General Virology|September 26, 2017
Mouse papillomavirus infections spread to cutaneous sites with progression to malignancyNancy M Cladel, Lynn R Budgeon, Timothy K Cooper, et al.
Journal of Virology|June 15, 2022
RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human CancerPola Olczak, Ken Matsui, Margaret Wong, et al.
Journal of Virology|November 14, 2014
A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragmentHyunwook Lee, Sarah A Brendle, Stephanie M Bywaters, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 22, 2020
An Integrated Approach for Preventing Oral Cavity and Oropharyngeal Cancers: Two Etiologies with Distinct and Shared Mechanisms of CarcinogenesisKaram El-Bayoumy, Neil D Christensen, Jiafen Hu, et al.
Vaccine|September 19, 2015
Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopesSubhashini Jagu, Balusubramanyam Karanam, Joshua W Wang, et al.
Pathogens (Basel, Switzerland)|December 22, 2023
Immune Responses in Oral Papillomavirus Clearance in the MmuPV1 Mouse ModelSarah A Brendle, Jingwei J Li, Vonn Walter, et al.
Antimicrobial Agents and Chemotherapy|April 29, 2009
GS-9191 is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesionsGrushenka H I Wolfgang, Riri Shibata, Jianying Wang, et al.
Vaccine|May 27, 2006
Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopesKenneth E Palmer, Ann Benko, Sarah A Doucette, et al.
Virology|May 12, 2005
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2Diana V Pastrana, Ratish Gambhira, Christopher B Buck, et al.
Viruses|September 28, 2021
Mouse Papillomavirus L1 and L2 Are Dispensable for Viral Infection and Persistence at Both Cutaneous and Mucosal TissuesSarah Brendle, Jingwei J Li, Nancy M Cladel, et al.
Pageof 13